115 related articles for article (PubMed ID: 12637645)
21. Vitamin D analogues for secondary hyperparathyroidism.
Brown AJ; Dusso AS; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():10-9. PubMed ID: 12386264
[TBL] [Abstract][Full Text] [Related]
22. Changes in the concentrations of vitamin D and its metabolites in the plasma of healthy subjects orally given physiological doses of vitamin D2 by multivitamin or vitamin D preparations.
Matsuoka M; Otsuka H; Masuda S; Okano T; Kobayashi T; Takeuchi T; Itokawa Y
J Nutr Sci Vitaminol (Tokyo); 1989 Aug; 35(4):253-66. PubMed ID: 2585147
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
[TBL] [Abstract][Full Text] [Related]
24. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
25. [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
Akiba T
Clin Calcium; 2007 May; 17(5):767-71. PubMed ID: 17471008
[TBL] [Abstract][Full Text] [Related]
26. Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism.
Costa AF; dos Reis LM; Ribeiro MC; Moysés RM; Jorgetti V
Nephrol Dial Transplant; 2003 Apr; 18(4):743-9. PubMed ID: 12637644
[TBL] [Abstract][Full Text] [Related]
27. Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study.
Fadem SZ; Al-Saghir F; Zollner G; Swan S
Clin Nephrol; 2008 Oct; 70(4):319-24. PubMed ID: 18826857
[TBL] [Abstract][Full Text] [Related]
28. Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group.
Frazao JM; Chesney RW; Coburn JW
Nephrol Dial Transplant; 1998; 13 Suppl 3():68-72. PubMed ID: 9568825
[TBL] [Abstract][Full Text] [Related]
29. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
[TBL] [Abstract][Full Text] [Related]
30. Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis.
Cipriani C; Romagnoli E; Pepe J; Russo S; Carlucci L; Piemonte S; Nieddu L; McMahon DJ; Singh R; Minisola S
J Clin Endocrinol Metab; 2013 Jul; 98(7):2709-15. PubMed ID: 23766519
[TBL] [Abstract][Full Text] [Related]
31. Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag transgenic mice.
Dawson DG; Gleiser J; Zimbric ML; Darjatmoko SR; Lindstrom MJ; Strugnell SA; Albert DM
Ophthalmology; 2003 Apr; 110(4):835-9. PubMed ID: 12689912
[TBL] [Abstract][Full Text] [Related]
32. Disposition and metabolism of F6-1alpha,25(OH)2 vitamin D3 and 1alpha,25(OH)2 vitamin D3 in the parathyroid glands of rats dosed with tritium-labeled compounds.
Komuro S; Sato M; Kanamaru H
Drug Metab Dispos; 2003 Aug; 31(8):973-8. PubMed ID: 12867483
[TBL] [Abstract][Full Text] [Related]
33. Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor.
Ritter CS; Brown AJ
J Mol Endocrinol; 2011 Apr; 46(2):63-6. PubMed ID: 21169421
[TBL] [Abstract][Full Text] [Related]
34. A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol.
Kubodera N
Molecules; 2009 Sep; 14(10):3869-80. PubMed ID: 19924035
[TBL] [Abstract][Full Text] [Related]
35. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
36. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.
Ohashi N; Uematsu T; Nagashima S; Kanamaru M; Togawa A; Hishida A; Uchida E; Akizawa T; Koshikawa S
Br J Clin Pharmacol; 2004 Jun; 57(6):726-34. PubMed ID: 15151518
[TBL] [Abstract][Full Text] [Related]
37. Response of a single 'mega intramuscular dose' of vitamin D on serum 25OHD and parathyroid hormone levels.
Khan AH; Rohra DK; Saghir SA; Udani SK; Wood R; Jabbar A
J Coll Physicians Surg Pak; 2012 Apr; 22(4):207-12. PubMed ID: 22482374
[TBL] [Abstract][Full Text] [Related]
38. Effects of vitamin D2-fortified bread v. supplementation with vitamin D2 or D3 on serum 25-hydroxyvitamin D metabolites: an 8-week randomised-controlled trial in young adult Finnish women.
Itkonen ST; Skaffari E; Saaristo P; Saarnio EM; Erkkola M; Jakobsen J; Cashman KD; Lamberg-Allardt C
Br J Nutr; 2016 Apr; 115(7):1232-9. PubMed ID: 26864127
[TBL] [Abstract][Full Text] [Related]
39. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly.
Romagnoli E; Mascia ML; Cipriani C; Fassino V; Mazzei F; D'Erasmo E; Carnevale V; Scillitani A; Minisola S
J Clin Endocrinol Metab; 2008 Aug; 93(8):3015-20. PubMed ID: 18492750
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
Brown AJ
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):578-83. PubMed ID: 17368185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
